Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (1047)	6/13/1999 9:25:00 PM
From: Dante Sinferno	Respond to of 1686

"Amevive is likely to be the primary choice where there really aren't any alternatives." Yup , I've got a mild case and while I can clear it up with PUVA or a few hundred milligrams/day of Zinc , the nausea I get is worse than the psoriasis. Very much looking forward to Amevive. rob

To: Harold Engstrom who wrote (1047)	6/15/1999 3:30:00 AM
From: Walkingshadow	Read Replies (1) \| Respond to of 1686

Harold-- Thanks for the post--good work! One question I have regards Adentri. CHF is an area where there are many current drugs already out, and many more in various pipelines. How do you think Adentri might fare against these drugs, and why? While you may talk about the size of the potential market, this does not seem as relevant as asking: What might be the ability of Adentri to grab market share and command sales, and how long might this last? (to answer this last question, you would have to compare Adentri's advantages/disadvantages to those of CHF drugs in other pipelines). Any thoughts on these questions? Thanks, Walkingshadow